Fort Collins, CO- Cardiost, Innosphere Client Company and innovative leader in cardiovascular solutions, proudly announces its win at the 2023 National Institute on Aging (NIA) Start-Up Challenge and Accelerator. As one of six distinguished winners, Cardiost, led by Nicolas Anzellini, MBA, and Fernando Anzellini, MD, stands at the forefront of innovation in healthcare technology.

The NIA Start-Up Challenge showcases the most promising ventures committed to enhancing the lives of aging adults and addressing health disparities within the aging population. Cardiost’s recognition among the winners underscores its dedication to revolutionizing cardiovascular care and improving the quality of life for diverse aging populations across the United States.

In recognition of their achievement, each of the six finalist companies, including Cardiost, will receive a $60,000 cash prize.

Reflecting on this achievement, CEO Nicolas Anzellini expressed, “We are honored to be recognized by the NIA and grateful for the opportunity to contribute to the advancement of healthcare for aging adults. This win reaffirms our commitment to innovation and our mission to make a meaningful impact on cardiovascular health.”

As an Innosphere Client Company, Cardiost exemplifies the spirit of entrepreneurship and dedication to excellence. The company’s implantable medical device offers groundbreaking solutions for heart failure and other cardiovascular conditions, promising transformative outcomes for patients worldwide.

Cardiost extends its heartfelt gratitude to the NIA for their support and recognition, as well as to its team, partners, and stakeholders for their unwavering commitment to advancing healthcare innovation.

To learn more please contact Nico Anzellini, CEO, at [email protected] or visit




Cardiost is a cutting-edge medical device startup focused on developing a durable heart-assist pump tailored for late-stage heart failure patients. Our innovative solution aims to alleviate the workload on hypertrophic or weakened left ventricles, thereby enhancing cardiac output and reducing pulmonary capillary wedge pressure. Collaborating with esteemed institutions like the Cardiovascular Biomechanics Lab at the University of Denver and the University of Colorado Boulder, we are optimizing our LAUD centrifugal pump and developing a proprietary induction